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Postoperative nausea and vomiting (PONV) is one of the most common and distressing
complications after general anesthesia and surgery, with young non-smoking females
receiving postoperative opioids being high-risk patients. This register-based study aims to
evaluate the effect of low-dose haloperidol (0.5 mg intravenously) directly after induction of
general anesthesia to reduce the incidence of PONV in the postoperative anesthesiological
care unit (PACU).
Methods
Multivariable regression models were used to investigate the association between low-dose
haloperidol and the occurrence of PONV using a patient registry containing 2,617 surgical
procedures carried out at an university hospital.
Results
Haloperidol 0.5 mg is associated with a reduced risk of PONV in the total collective
(adjusted odds ratio = 0.75, 95% confidence interval: [0.56, 0.99], p = 0.05). The results indi-
cate that there is a reduced risk in male patients (adjusted odds ratio = 0.45, 95% confi-
dence interval: [0.28, 0.73], p = 0.001) if a dose of 0.5 mg haloperidol was administered
while there seems to be no effect in females (adjusted odds ratio = 1.02, 95% confidence
interval: [0.71, 1.46], p = 0.93). Currently known risk factors for PONV such as female gen-
der, duration of anesthesia and the use of opioids were confirmed in our analysis.
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Conclusion
This study suggests that low-dose haloperidol has an antiemetic effect in male patients but
has no effect in female patients. A confirmation of the gender-specific effects we have
observed in this register-based cohort study might have major implications on clinical daily
routine.
Introduction
Postoperative nausea and vomiting (PONV) is a common and distressing complication follow-
ing anesthesia and surgery and can result in dehydration, electrolyte imbalance, wound dehis-
cence, pulmonary aspiration and delayed hospital discharge [1, 2]. PONV is considered by
many patients to be more distressing than surgical pain [3, 4]. The risk of developing PONV
without pharmacological prophylaxis varies from about 20–30% overall to 70% depending on
the patients’ baseline risk factors [5–8] and is a substantial economic factor [8]. In the last
decade, several risk scores and pharmacological strategies have been evaluated to reduce the
probability of suffering from PONV [9–13]. One of the pharmacological strategies to reduce
PONV is the application of haloperidol, a neuroleptic drug with a further indication as an anti-
emetic substance [13–15]. Several studies investigated its effectiveness on preventing PONV.
Most of the studies were performed with doses of at least 1 mg haloperidol intravenously (i.v.)
or in combination with other antiemetic drugs like dexamethasone or ondansetron [16–20].
To our best knowledge, there are no data available demonstrating gender effects of haloperidol
used as an antiemetic drug.
Following the Food and Drug Administration (FDA) warning for droperidol, haloperidol
was established in our hospital as one prophylactic medication against PONV. Since side effects
such as dystonia or tardive dykinesia were observed when using higher dosages, e.g., 2 mg, the
current standard used in our hospital for PONV prophylaxis is 0.5 mg haloperidol.
This register-based retrospective cohort study aimed to evaluate the effect of low-dose halo-
peridol (0.5 mg i.v.) directly after the induction of general anesthesia for the prevention of
PONV in the postoperative anesthesiological care unit (PACU), while adjusting for confound-
ers like gender, age, BMI, smoking status, ASA status (preoperative classification of the Ameri-
can Society of Anaesthesiologists), type and duration of anesthesia and use of opioids. The
structure of this paper follows the STROBE guidelines for reporting observational studies.
Methods
The study was approved by the Ethics Committee of the Ludwig-Maximilians-University
Munich (no. 042–13, accepted 01/30/2013). The Ethics Committee waived the requirement for
informed consent from the participants in the study. We obtained data from a patient registry
of the Department of Anaesthesiology at the University Hospital of Munich in which informa-
tion on all anesthesiological procedures is routinely electronically documented. Patient data
was anonymized and de-identified prior to access and analysis. It is available as S1 Dataset. The
data has not been considered for any other study.
This register-based cohort study comprised a group of patients having received a dose of
0.5 mg haloperidol i.v. (haloperidol group) and a group of patients not having received any
antiemetic drugs for prevention of PONV (non-haloperidol group). Due to a long elimination
half-life time (about 15 h) and a potential intraoperative initiation of the antiemetic effect, hal-
operidol was applicated directly after induction of general anaesthesia [21].
Haloperidol for Prevention of Postoperative Nausea and Vomiting
PLOS ONE | DOI:10.1371/journal.pone.0146746 January 11, 2016 2 / 15
Information on patient characteristics and surgical details were retrieved from a patient reg-
istry where data were documented according to a standard protocol. Each anesthesiological
procedure at the University Hospital of Munich is routinely recorded using the online docu-
mentation software NarkoData1 (Ver. 4.7.0.3, IMESO GmbH, Giessen, Germany).
All patients receiving general anesthesia with successive surgery within the period 01/07/
2008–06/19/2012 at the University Hospital of Munich were considered for this study. The
inclusion criteria were: age of at least 18 years and having received a surgical procedure in the
domain of urology, gynecology or general surgery (including laparotomy and opening of the
retroperitoneal space, operations at the kidney, cystectomy, replacement of the urinary bladder,
other operations at the urinary organs, excision and destruction of prostate tissue, radical pros-
tatectomy, local excision and destruction of ovarial tissue, oophorectomy, hysterectomy, par-
tially excision of the mammarian glandula and destruction of mammarian tissue, excision and
resection of the mammarian glandula). Patients who received a different dose than 0.5 mg hal-
operidol were excluded as well as patients who received other antiemetic drugs such as ondan-
setron before or during anesthesia.
Early PONV was defined if patients received ondansetron as rescue treatment antiemetic
drug after the surgical procedure in the recovery room (according to our clinical standard). In
this context “early” refers to the time period from extubation until discharge from the PACU
[22]. Ondansetron was only used as a therapeutic drug for the treatment of PONV in the
PACU. Patients received either no haloperidol (non-haloperidol group) or a dose of 0.5 mg
haloperidol applied intravenously directly after induction of general anesthesia (haloperidol
group).
Due to a low number of ASA 4 patients, ASA 3 and 4 patients were pooled into one category
ASA 3–4.
Data concerning intravenous drugs, epidural drugs and preoperative patient data (e.g. his-
tory of PONV, smoking status) were documented manually during the surgical procedure by
the treating anaesthesiologist. Data concerning the volatile anaesthetics (maximum and aver-
age concentrations) were documented automatically online by the anesthesia documentation
software NarkoData.
Patient characteristics were entered from a standard paper-based protocol in a database
(single data entry). Consistency checks were done before performing the statistical analysis.
The number of surgical procedures that fulfilled the inclusion and exclusion criteria and
were conducted within the period 01/07/2008–06/19/2012 at the University Hospital of
Munich determined the sample size.
In observational studies the treatment is not randomized within the patient population.
Therefore, systematic differences in the characteristics of the treatment and the control group
can occur. In order to avoid biased treatment effect estimates appropriate statistical analyses
such as multivariable regression or propensity score analyses have to be used to address this
problem [23, 24]. We applied both procedures to account for the problem of systematic differ-
ences between the haloperidol and the non-haloperidol group.
To assess the patients’ baseline risks for PONV, the Apfel score was computed which is a
simplified risk score for predicting the patient’s risk for PONV within 24h of surgery [12, 25].
It corresponds to the number of risk factors out of the following factors: female gender, history
of PONV, non-smoking and the use of postoperative opioids (here: piritramide). Apfel scores
of 0, 1, 2, 3, 4 correspond to PONV risks of 10%, 20%, 40%, 60% and 80%.
A chi-square test was performed for testing whether PONV incidences differed between the
haloperidol and the non-haloperidol group. A Mann-Whitney-U test was used for testing
whether duration of stay in the recovery room was different between patients with PONV and
patients without PONV.
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A logistic additive model with the outcome “occurrence of PONV” was used. Besides the
variable indicating if the patient had received haloperidol, our model included all the con-
founder variables which were known from the literature and were documented in the patient
registry, namely: gender, age, BMI, smoking status, previous PONV, type of surgical procedure,
combination anesthesia (general plus epidural anesthesia), duration of anesthesia, dose of
sufentanil, remifentanil, piritramide, sevoflurane and propofol. No preceding variable selection
was performed. The effects of all metric covariates in the additive model were modeled by
smooth functions, that allow for a flexible modelling. Tuning parameters that control the wigg-
liness of the curves were adjusted via generalized cross-validation implemented in the R pack-
age mgcv [23]. 95% pointwise confidence limits were computed that indicate whether the odds
ratio (OR) at a given predictor value significantly differs from 1. This is the case if the confi-
dence interval (CI) for the log OR does not cover the value zero. Apart from all main effects an
interaction effect between haloperidol and gender was included into the model to allow for the
estimation of gender-specific associations between haloperidol and PONV (the decision of
including the interaction was made based on a post-hoc analysis).
In a secondary analysis, we used propensity score methods for confounder adjustment in
the population of female and male patients to see if results from propensity score analysis are
consistent with those obtained from multivariable regression.
In a second model the duration of stay in the recovery room for patients having PONV was
compared to the duration of stay for patients not having PONV while adjusting for the con-
founder variables gender, age, BMI, smoking status, history of PONV, type of surgical proce-
dure, combined anesthesia, haloperidol for prophylaxis of PONV, dose of sufentanil,
remifentanil, piritramide, sevoflurane and propofol. A linear additive regression model was
used that includes all main effects and the interaction between haloperidol and gender. A loga-
rithmic transformation was performed on the response variable “duration of stay”.
Statistical analysis was performed using the statistical software R (version 3.0.1).
Results
A total of 2,668 surgical procedures documented in the patient registry fulfilled the inclusion
criteria (Fig 1). Information on 51 surgical procedures was excluded from analysis due to incor-
rect documentation (see Fig 1). Data from 2,617 surgical procedures remained for statistical
analysis.
Patient characteristics are shown in Table 1. In 1,272 of the 2,617 surgical procedures
(48.6%) haloperidol was administered, while in the remaining 1,345 no prophylactic antiemetic
substance was administered. Pronounced differences between the haloperidol and the non-hal-
operidol group were seen for gender, ASA status, surgical procedures, age, kind of anesthesia,
anesthetic drug characteristics. This illustrates the need for appropriate statistical methods to
adjust for differences between the groups.
Fig 2 shows the baseline risks for PONV in the haloperidol group and in the non-haloperi-
dol group according to the Apfel score. There is a preferential application of haloperidol for
patients with higher Apfel scores. For example in the non-haloperidol group approximately
50% of the patients have an Apfel score of 0 or 1, while in the haloperidol group only about
35% have an Apfel score equal or less than 1. This underlines the need for risk factor adjust-
ments when assessing the use of haloperidol for the prevention of PONV.
In total 338 patients (12.9%) suffered early PONV (i.e., PONV in PACU). The average
length of stay in PACU was 150±83 min. There were no differences in the incidence of PONV
between the non-haloperidol group (n = 178; 13.2%) and the haloperidol group (n = 160;
12.6%), giving an unadjusted odds ratio of 0.94 (95% CI: [0.75, 1.19]) in the total patient
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collective (p = 0.66). In the female population 18.5% of the patients had PONV and 7.9% had
PONV in the male population. The unadjusted odds ratio for the effect of haloperiol in the sub-
group of females and males, respectively, was 0.87 (95% CI: [0.65, 1.16], p = 0.37) and 0.54
(95% CI: [0.35, 0.84], p = 0.008).
The multivariable regression model confirmed risk factors for PONV, which are reported in
the literature. These factors determine subgroups of patients with a specific PONV risk. The
PONV risk spectrum for male patients when not treated with haloperidol ranges from 0 to
57%. When treated with haloperidol each male subgroup risk changes by the OR of 0.45 (95%
CI for the OR: [0.28, 0.73], p = 0.001). The PONV risk spectrum for female patients when not
treated with haloperidol ranges from 0 to 86%. For female patients the adjusted OR is close to
1, which corresponds to no change in PONV risk when haloperidol is administered.
When not integrating an interaction between gender and haloperidol, an adjusted OR of
0.75 was obtained for the total patient collective (p = 0.05).
The adjusted ORs and 95% CI for the confounding variables estimated via the multivariable
regression model are shown in Table 2. For metric variables an OR is provided if the effect is
nearly linear, otherwise the effect (in terms of the log OR) is described via a smooth curve
Fig 1. Enrollment. Enrollment of surgical procedures into the analysis.
doi:10.1371/journal.pone.0146746.g001
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Table 1. Patient characteristics.





Male 52.7% 41.1% 63.6%
Female 47.3% 58.9% 36.4%
Smoking status
Smoker 15.6% 14.5% 16.6%
Non-smoker or unknown 84.4% 85.5% 83.4%
History of PONV
Positive 2.5% 2.4% 2.5%
Negative or unknown 97.6% 97.6% 97.5%
ASA
ASA 1 10.9% 15.3% 6.8%
ASA 2 52.1% 59.4% 45.3%
ASA 3–4 37.0% 25.4% 48.0%
Surgical
procedure
Laparotomy and opening of the
retroperitoneal space
29.1% 18.0% 39.6%
Operations at the kidney 17.5% 12.6% 22.2%
Cystectomy 1.4% 2.1% 0.7%
Replacement of the urinary bladder 3.7% 3.9% 3.4%
Other operations at the urinary organs 11.7% 12.3% 11.0%
Excision and destruction of prostate tissue 8.0% 7.4% 8.6%
Radical prostatectomy 7.8% 8.0% 7.5%
Local excision and destruction of ovarial
tissue
3.3% 6.1% 0.7%
Oophorectomy 1.3% 2.0% 0.6%
Hysterectomy 7.2% 12.2% 2.5%
Partial excision of the mammarian glandula
and destruction of mammarian tissue
5.5% 9.0% 2.1%





Yes 46.5% 44.3% 48.6%
No 53.5% 55.7% 51.5%
Age [years] 60.9 ± 13.4 60.0 ± 13.7 61.7 ± 13.0
BMI [kg/m2] 26.3 ± 4.8 26.4 ± 4.8 26.2 ± 4.9
Anesthesia
duration [min]
184.0 ± 89.0 194.7 ± 94.7 173.9 ± 82.0
Sufentanil
Epidural (bolus)
0 μg 56.7% 57.6% 55.8%
10 μg 42.6% 41.5% 43.6%
20 μg 0.7% 0.9% 0.6%
Intravenous (bolus), [μg] 44.6 ± 21.3 a; n = 1979
a
45.4 ± 20.0 a; n = 910 a 43.9 ± 22.3 a; n = 1069 a
Intravenous (infusion, peak rate), [μg/h] 42.7 ± 17.1 b; n = 26 b 47.3 ± 20.2 b; n = 15 b 36.4 ± 9.2 b; n = 11 b
Intravenous (TCI, total dose), [μg] 74.6 ± 38.5 c; n = 71 c 71.1 ± 24.9 c; n = 55 c 86.6 ± 67.0 c; n = 16 c
(Continued)
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(Fig 3). The effects were non-linear for the duration of anesthesia, total intravenous sufentanil,
remifentanil and piritramide application as well as for the maximum continuous rate of
propofol.
There is a significant effect for gender indicating that female patients have an approx. 3-fold
higher risk for PONV than male patients with similar characteristics (p<0.0001). No associa-
tion was observed between age or BMI and the risk for PONV. A slightly higher but non-signif-
icant risk can also be seen for non-smokers compared to smokers (OR = 1/0.78 = 1.28,
p = 0.20). Patients with positive history of PONV have a higher risk for PONV (OR = 1.59,
p = 0.17) compared to patients who have never experienced PONV before or for whom no
information regarding PONV history was available, though also this association is not statisti-
cally significant. The risk for PONV is reduced with increasing ASA status (p = 0.001). Patients
with ASA 2 have a risk that is significantly lower at factor 0.56 (p = 0.008) and for patients with
Table 1. (Continued)





Intravenous (bolus), [μg] 95.4 ± 47.7 d; n = 13 d 94.3 ± 32.1 d; n = 7 d 96.7 ± 65.0 d; n = 6 d
Intravenous (infusion, peak rate), [μg/h] 755.4 ± 372.6 e;
n = 579 e
778.6 ± 390.6 e;
n = 310 e
728.7 ± 349.5 e; n = 269 e
Intravenous (TCI, total dose), [μg] 1,473.1 ± 1,003.3 f;
n = 468 f
1,523.9 ± 1,076.0 f;
n = 295 f
1,386.6 ± 861.6 f;
n = 173 f
Piritramide
Intravenous (bolus), [mg] 10.7 ± 7.2 g; n = 778 g 9.1 ± 5.9 g; n = 373 g 12.1 ± 7.9 g; n = 405 g
Sevoflurane
Max. conc. [Vol%et] 1.84 ± 0.76
h; n = 499 h 1.84 ± 0.82 h; n = 195 h 1.84 ± 0.72 h; n = 304 h
Average conc. [Vol%et] 0.93 ± 0.65
i; n = 544 i 0.92 ± 0.68 i; n = 212 i 0.94 ± 0.64 i; n = 332 i
Propofol
Intravenous (bolus), [mg] 198.1 ± 53.6 k;
n = 1,902 k
197.5l ± 51.1 k; n = 845 k 198.6 ± 55.5 k; n = 1,057 k
Intravenous (infusion, peak rate), [mg/h] 441.3 ± 100.7 l;
n = 1,797 l
440.0 ± 91.9 l; n = 811 l 442.3 ± 107.4 l; n = 986 l
Intravenous (TCI, total dose), [μg] 1,450.1 ± 749.4 m;
n = 580 m
1,471.5 ± 745.9 m;
n = 382 m
1,408.8 ± 756.3 m;
n = 198 m
Patient characteristics documented for the 2,617 surgical procedures that were used for the statistical analysis overall, in the subgroup of patients having
received haloperidol (haloperidol group) and in the subgroup of patients having not received any antiemetic substance (non-haloperidol group). For
categorical variables percentages are given, for continuous variables the mean value ± standard deviation is given.
a Sufentanil bolus > 1μg
b Sufentanil continuous rate  10mg/h
c Sufentanil TCI total dose > 1μg
d Remifentanil i.v. > 0μg
e Remifentanil continuous rate > 0μg/h
f Remifentanil TCI total dose > 10μg
g Piritramide dosage > 0mg
h maximum endtidal sevoflurane concentration > 0.3%
i Average sevoflurane concentration > 0
k Propofol i.v. bolus > 0mg
l Propofol continuous peak rate > 20mg/h
m Propofol TCI total dose > 1mg. Sufentantil and remifentanil were given only intraoperatively, whereas piritramide was applicated only in the PACU.
doi:10.1371/journal.pone.0146746.t001
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ASA 3 or 4 the risk is even lower at factor 0.41 (p<0.001), when compared to patients with
ASA 1. Significant differences were also observed between different surgical procedures
(p<0.001): patients receiving an operation at the urinary organs have the lowest risk for
PONV, while those with excision and destruction of prostate tissue have the highest risk. The
risk for latter patients is about 17 (= 1.68/0.1) times higher compared to patients with surgery
on the urinary organs, indicating huge risk differences depending on the surgical procedure.
ORs for other surgical procedures (when compared to laparotomy and opening of the retroper-
itoneal space) are shown in Table 2. Patients receiving combined anesthesia have almost the
same risk for PONV as patients receiving general anesthesia alone (OR = 1.12, p = 0.77).
Fig 3(A) shows the non-linear effect of the duration of anesthesia on the risk of PONV. The
black line corresponds to the estimated log OR, which depends on the specific values for dura-
tion of anesthesia. The grey regions are pointwise confidence intervals, and in this case are very
narrow indicating a precise estimation of the log OR. Fig 3(A) shows a linear increase in the
risk for PONV with increasing anesthesia durations up to 200 min; for durations above 200
min, the risk of PONV stays constantly high and does not further increase for higher durations.
From this graphical representation one can for instance see that a patient with an anesthesia
duration of 300 min has an about twice (= exp(0.65)) higher risk compared to a patient with an
average duration of 184 min.
Regarding the administration of sufentanil, remifentanil and piritramide, the results indi-
cate that the higher the total dose / peak rate, the higher the patient’s risk for developing
PONV. Patients have a doubled risk for PONV when having received 10 μg sufentanil epidu-
rally (p = 0.04). Increasing dosages of piritramide lead to an increasing risk of PONV (Fig 3
(D)). With values above 15 mg, the effect does not further increase but stays constantly high.
The effects of sufentanil (total bolus dose, infusion rate) and remifentanil (total bolus dose,
infusion rate, target-controlled-infusion total dose) were not significant. For sufentanil (infu-
sion rate) and remifentanil (bolus) this might possibly be attributable to the low statistical
power to detect significant associations because of the small numbers of patients having
Fig 2. Apfel scores.Relative frequency of patients with Apfel scores 0–4 in the haloperidol group and in the non-haloperidol group.
doi:10.1371/journal.pone.0146746.g002
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Table 2. Adjusted Odds Ratios.
Variable OR 95% CI p-value
Haloperidol–male 0.45 [0.28, 0.73] 0.001
Haloperidol–female 1.02 [0.71, 1.46] 0.93
Interaction: haloperidol, female 2.25 [1.25, 4.05] 0.007
Gender (reference: male) 2.66 [1.80, 3.93] <0.001
Smoking status (reference:
non-smoker)
0.78 [0.54, 1.13] 0.20
History of PONV (reference:
negative)
1.59 [0.82, 3.05] 0.17
ASA (reference: ASA 1) 0.001a
ASA 2 0.56 [0.37, 0.86] 0.008
ASA 3–4 0.41 [0.25, 0.66] <0.001
Surgical procedure (reference:
Laparotomy and opening of the
retroperitoneal space)
<0.001a
Operations at the kidney 0.74 [0.51, 1.06] 0.10
Cystectomy 1.09 [0.41, 2.94] 0.86
Replacement of the urinary bladder 0.71 [0.35, 1.44] 0.34
Other operations at the urinary organs 0.10 [0.02, 0.45] 0.002
Excision and destruction of prostate tissue 1.68 [0.97, 2.91] 0.06
Radical prostatectomy 0.64 [0.32, 1.26] 0.19
Local excision and destruction of ovarial tissue 0.25 [0.09, 0.70] 0.008
Oophorectomy 0.54 [0.15, 1.95] 0.35
Hysterectomy 0.73 [0.46, 1.17] 0.19
Partial excision of the mammarian glandula and destruction of
mammarian tissue
0.50 [0.23, 1.06] 0.07
Excision and resection of the mammarian glandula 0.40 [0.17, 0.94] 0.04
Combined anesthesia 1.12 [0.52, 2.41] 0.77
Age (+ 10 years) 1.00 [0.90, 1.11] 0.96
BMI (+ 5 kg/m2) 1.08 [0.95, 1.23] 0.23
Anesthesia duration - - <0.001
Sufentanil










Intravenous (infusion, continuous rate; + 25 μg) 0.92 [0.42, 1.99] 0.83
Intravenous (TCI, total dose; + 10 μg) 1.10 [1.00, 1.21] 0.05
Remifentanil
Intravenous (bolus, + 100 μg) 0.79 [0.13, 4.89] 0.80
Intravenous (infusion, continuous rate; + 100 μg) 1.01 [0.98, 1.05] 0.48
Intravenous (TCI, total dose) - - 0.20
Piritramide
Intravenous (total dose) - - <0.001
Sevoflurane
Average concentration (+ 0.1 Vol%et) 0.96 [0.90, 1.02] 0.15
Max. concentration (+ 1 Vol%et) 1.52 [1.07, 2.16] 0.02
Propofol
(Continued)
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received these opioids (n = 26 and n = 13, respectively; see Table 1). However, most of them
have a trend towards an increased risk for higher values. A clear trend can for instance be
observed for the effect of remifentanil when administered by target-controlled-infusion (TCI)
of anesthesia (Fig 3(C)): for total doses below 5 g there is a nearly linear trend towards a higher
risk of PONV.
There is also a significant increase in the risk for PONV for higher maximal concentrations
of sevoflurane (p = 0.02): The risk for PONV is larger at factor 1.52 for an increase by 1 Vol-
ume% endtidal. However, there was no significant effect for the average concentration
(p = 0.15).
For higher total doses of propofol applicated via TCI there is a linear decrease for the risk of
PONV (p = 0.003). The OR for an increase of the total dose by 200 mg is 0.9. The effect of pro-
pofol infusion is shown in Fig 3(E) (p = 0.03). There is an initial slight increase in risk for values
between 0 and 200 mg/h. For values above, there is a trend towards a reduced risk.
The results of propensity score analyses were in line with the results that were obtained
from multiple regression. Marginal ORs (obtained using several different approaches) consis-
tently indicated a substantially reduced risk for PONV in the male patient population and a
constant or slightly reduced risk in the female patient population when receiving haloperidol
(data not shown).
In the univariate analysis the average length of stay in the recovery room was 150±83 min
overall, 200±87 min in the group of patients with PONV and 142±80 min in the group of
patients without PONV in PACU (p<0.001). When adjusting for confounders by multivariable
analysis an increased duration of stay in the recovery room by factor 1.31 (95% CI: [1.24, 1.39],
p<0.0001) was observed for patients suffering from PONV.
Discussion
Regression analyses on observational data are able to quantify associations between the out-
come variable and covariates of interest. In this sense, a different association between the risk
for PONV and low-dose haloperidol was detected in male and female patients from a register-
based cohort study. Recent developments in causal statistics allow interpreting associations
also in terms of effects. Especially the development of propensity scores strengthens this
approach. Our additional analyses based on propensity score strategies agree with our tradi-
tional regression approach. Therefore, the data also indicates that low-dose haloperidol lowers
the risk for PONV in male patients (OR = 0.45), while for female patients it shows no effect
concerning the risk for PONV (OR = 1.02). With the use of generalized additive regression
models we confirmed risk factors which were already known from the literature, such as female
Table 2. (Continued)
Variable OR 95% CI p-value
Intravenous (bolus; + 50 mg) 0.96 [0.84, 1.08] 0.48
Intravenous (infusion, continuous rate, mg/h) - - 0.03
Intravenous (TCI, total dose; + 200 mg) 0.90 [0.84, 0.96] 0.003
Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values (Wald test) computed from a multivariable logistic additive regression model
which includes the interaction between haloperidol and gender.—indicates that the estimated effect is non-linear and can only be described via a graph
(Fig 3).
a p-value resulting from the Wald test for testing all levels of the respective covariate.
Vol%et = Volume% endtidal.
doi:10.1371/journal.pone.0146746.t002
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Fig 3. Nonlinear covariate effects. Estimated nonlinear effects of anesthesia duration (A), intravenous sufentanil (B), remifentanil TCI total dosage (C),
piritramide intravenous (D) and propofol infusion maximum rate (E). The solid black line visualizes the estimated effect (measured on log OR scale), the grey
region corresponds to the 95% pointwise confidence interval for the estimated effect. The marks along the x-axis indicate the observed covariate values in
the data.
doi:10.1371/journal.pone.0146746.g003
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gender, ASA status, the use of inhalational anesthesia and opioids [12, 25, 26]. In the present
study a significant difference in the risk for PONV depending on the type of surgical procedure
being performed was detected (p<0.001).
In general, it is difficult to obtain unbiased treatment effects from observational studies as
these are prone to bias and confounded by factors related to the treatment and the outcome.
We applied multivariable regression as well as propensity score analyses in order to address
this problem. To our best knowledge, this is the first study to investigate gender differences of
the PONV-reducing effects of low-dose haloperidol in surgical patients. Most of the studies
evaluated haloperidol dosages higher than 0.5 mg [27–30] or in a selected female collective [16,
29, 31]. Interestingly, several studies detected high effectiveness of haloperidol in reducing
PONV in female patients [16, 20, 31, 32], whereas others only report a weak or no effect [16,
33]. Buettner and colleagues found in their meta-analysis lack of efficacy for 0.25 mg haloperi-
dol and different numbers needed-to-treat in dependence of the dosage (0.5–4 mg) [14]. In the
present study there was only evidence for a PONV lowering effect of 0.5 mg haloperidol in
male patients, so that a gender effect of haloperidol could be assumed. Zhang-Wong and col-
leagues demonstrated that gender may possibly affect haloperidol metabolism at least after oral
application [34]. In female rats haloperidol leads to a striatal dopamine efflux twice as large as
in male rats. Moreover, Arenas and colleagues could demonstrate that gender-specific differ-
ences are dose dependent in studies investigating the effect of haloperidol on escape-avoidance
in mice. They demonstrated a decreased effect in female animals in low dose applications [35–
37], while there was no difference in effects between male and female animals when using
higher doses of haloperidol. These findings suggest gender-specific differences also in humans
when using small doses of haloperidol.
Potentially, a higher dosage could be effective in females as indicated by the many studies
mentioned above. However, most of these studies do not report results for early PONV, which
is considered in this paper. In the study by Chu et al. it was reported that PONV occurred
within the first 2 hours in 8% of the female patients having received 2 mg Haloperidol intrave-
nously and in 12% of the female control group (no statistically significant difference) [31]. In
the study of Tornetta, an antiemetic effect of 0.5 mg for reducing PONV within 24 hours after
surgery in females was shown [15]. However, we are not aware of any studies that evaluate the
effect of 0.5 mg haloperidol on early PONV in female patients.
Similar to many other studies, in this study, haloperidol was administered immediately after
induction of anesthesia. In a randomized double-blind trial it was shown that there was no dif-
ference in the risk for PONV for patients having received haloperidol during induction of anes-
thesia and patients having received haloperidol 30 min before the end of surgery [38]. Thus the
results of our study are not affected by the timing of the administration of haloperidol.
In this paper, early PONV was diagnosed if patients received ondansetron as a rescue treat-
ment antiemetic drug after the surgical procedure in the recovery room. However, no data was
available from the patient registry which measures the severity of PONV. Some studies have
also evaluated the severity of PONV based on absolute counts, Likert scales or visual analogue
scales. Such scores could be used for a more detailed aquisition of PONV severity.
The mean duration in the recovery room until PACU discharge was 2 1/2 hours in our
patient collective. Within this time period, a total of 338 patients (12.9%) in the non-haloperi-
dol group had PONV. This number was much smaller than the number of patients with
PONV within 24 hours of surgery which is predicted by the Apfel score (12.9% observed versus
33.1% predicted). The reason for this difference might be that many patients develop PONV in
the delayed postoperative period. In the study of Chu et al. only about 20% of the patients who
suffered from PONV within 24 hours after surgery, had PONV in the first two hours [15]. In
other studies similar delayed and early PONV rates were observed [39]. As indicated by some
Haloperidol for Prevention of Postoperative Nausea and Vomiting
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studies the risk factors for early and delayed PONV differ, which might explain the differences
in the occurrence of delayed and early PONV in these studies [40, 41]. Apfel et al., for example,
showed that volatile anesthetics, such as sevoflurane, as well as its dosage are the strongest risk
factor for early PONV, while it has less effect on the risk for delayed PONV. In our patient
cohort only a small fraction of the patients received volatile anesthetics, which might be one
reason for the small number of patients with early PONV [40].
Although this is a single-center study conducted at an university hospital, the results should
be generalizable since the surgical procedures that were included are standard procedures and
the respective patient populations should not differ from patients at smaller hospitals.
The most relevant limitation concerns the study design per se, which is purely observational.
Although the registry contains all confounders reported in the literature, the possibility that
unknown confounders exist which may bias our results cannot be excluded. Further studies,
that are not affected by unmeasured confounders, such as randomized controlled trials, are
necessary to validate our findings. Albeit our study does not give definitive evidence for a gen-
der-specific effect of low-dose haloperiol, this finding, which is based on a comprehensive and
carefully conducted analysis of a large patient cohort, deserves further investigations because if
validated in future studies, it has an impact on clinical daily routine and reveals unexplored dif-
ferences in mechanisms between men and women.
Besides the study design, the suspected incomplete documentation of smoking status and
history of PONV might be considered as a problem. Compared with community prevalence of
smoking status or PONV history our values seem to be too low for both parameters [6, 42, 43].
However, the imprecise documentation should not lead to systematic bias of effect estimates of
any variable since the missing mechanism for smoking status and history of PONV should be
completely at random. Instead, we expect the incomplete documentation to only affect the
power of our analysis to detect a significant association between PONV and smoking status or
between PONV and history of PONV, respectively. Our analysis indicated an increased risk for
non-smokers and for patients with history of PONV, both being consistent with findings of
other studies. However, these associations were not significant which we expect is due to the
incomplete documentation and the resulting loss in statistical power.
The present study indicated a gender dependent effect of low-dose haloperidol concerning
reduction of postoperative nausea and vomiting in male patients. There was no indication of
risk reduction by the use of haloperidol in female patients. Our findings are based on an obser-
vational study. Further studies which are carefully conducted–preferably, randomized con-
trolled trials, are needed to validate these findings.
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